Dr_MSU Profile Banner
Mehmet S Uyanik, MD Profile
Mehmet S Uyanik, MD

@Dr_MSU

Followers
2K
Following
2K
Media
862
Statuses
3K

Stem Cell Transplantation and Cellular Therapies Fellow at Mayo Clinics, FL

Jacksonville, FL
Joined June 2021
Don't wanna be here? Send us removal request.
@Dr_MSU
Mehmet S Uyanik, MD
1 year
🗣:🇱🇷/👥️:👨‍👩‍👧‍👦💭.Dum vivis, sperare debet. (=As long as you live you must hope.)
Tweet media one
1
0
11
@Dr_MSU
Mehmet S Uyanik, MD
23 days
RT @CanerSaygin: Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN. Ca….
Tweet card summary image
nature.com
Leukemia - Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma
0
24
0
@Dr_MSU
Mehmet S Uyanik, MD
25 days
RT @DrHKantarjian: SQ blinatumomab is highly effective in R-R ALL with CR/CRh rate of 77%, MRD-negativity rate of 91%, and 12-month OS rate….
0
29
0
@Dr_MSU
Mehmet S Uyanik, MD
1 month
Those who have retained their Shibumi can discern a good soul by observing the surrounding atmosphere of this great personality!.
@Fparrhesia
Felsefe Parrhesia
1 month
“İyi bir insanı nasıl tanırsınız?”
0
0
0
@Dr_MSU
Mehmet S Uyanik, MD
1 month
RT @NitinJainMD: 👉Here is an updated version of the Table which I initially posted post ASH2024. 👉Now Updated with EHA 2025 data including….
0
41
0
@Dr_MSU
Mehmet S Uyanik, MD
1 month
RT @NitinJainMD: 👉👉We report case series of 6 patients with T-ALL/LBL who developed rhabdomyolysis after receiving nelarabine .👉 Check CK i….
0
15
0
@Dr_MSU
Mehmet S Uyanik, MD
1 month
🗣:🇺🇸/👥️:👨‍⚕️🩺🤣.The orientation module on hand hygiene is designed for fellows, assuming their prior knowledge of hand hygiene practices, as outlined below ⤵️
0
0
0
@Dr_MSU
Mehmet S Uyanik, MD
1 month
RT @abouabdrahman0: 🧵 Nivolumab-AVD vs BV-AVD in Older cHL (S1826) 🩺🩻. 1️⃣ Population:.•cHL ≥60y (median 66) advanced stage (III-IV).•99 pa….
0
7
0
@Dr_MSU
Mehmet S Uyanik, MD
2 months
RT @Yale: A new Yale study shows for the first time that immune-system T cells are present in the brain, sent by the gut to a region that r….
0
277
0
@Dr_MSU
Mehmet S Uyanik, MD
2 months
🗣:🇹🇷/👥️:👨‍👩‍👦🤣.Bence ulaştırma bakanlığı, kara yolları genel müdürlüğü ve trafik şube el ele verip tüm radarlardan önce John Carpenter'dan "The End" (Tabiri diğerle meşhur Nuri Alço Operasyon Müziği) melodisini çaldırsın sürücülere!. https://=hmZS4yMglDMHWh_p…
@bosunatiklama
Boşuna Tıklama
3 months
Türkiye'de ilk 'Melodili Yol' yapıldı. • Sürücüler belirli bir hızda Mozart'ın Türk Marşı bestesini duyabiliyor.
0
0
0
@Dr_MSU
Mehmet S Uyanik, MD
2 months
RT @BloodJournal: Cyclophosphamide to ablate CAR T cells is an effective strategy to mitigate steroid-refractory neurotoxicity syndrome neu….
Tweet card summary image
ashpublications.org
Distinct from other chimeric antigen receptor (CAR) therapies, B-cell maturation antigen–targeted CAR T-cell therapy can cause non-immune effector cell–ass
0
25
0
@Dr_MSU
Mehmet S Uyanik, MD
2 months
Rare Complications of CART Cells:
Tweet media one
0
0
1
@Dr_MSU
Mehmet S Uyanik, MD
2 months
Lovely presentation regarding Late Toxicities of CART Cells @ASCO 2025 by Dr. Abramson from Mass General.
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
0
1
@Dr_MSU
Mehmet S Uyanik, MD
2 months
Self Selected Oscar for the Best Slides on ASCO25 goes to Michael D. Jain from Moffitt Cancer Center FL.
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
0
3
@Dr_MSU
Mehmet S Uyanik, MD
2 months
RT @AML_Hub: CONGRESS | #ASCO25 | POSTER.Mehmet Uyanik @Dr_MSU @MDAndersonNews shares efficacy and safety results from a phase II trial (NC….
0
1
0
@Dr_MSU
Mehmet S Uyanik, MD
2 months
ASCO25 Novel Aprroaches Regarding DLBCL
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
0
2
@Dr_MSU
Mehmet S Uyanik, MD
2 months
In vivo CAR T-cell therapy offers advantages such as reduced production time, minimized cytokine release, and a lower risk of secondary malignancies, representing a promising advancement in the field.
@Nature
nature
2 months
Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get this powerful therapy to more people.
0
0
0
@Dr_MSU
Mehmet S Uyanik, MD
2 months
Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in patients with COPD.
@Medscape
Medscape
2 months
Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the MATINEE study presented at the American Thoracic Society (ATS) 2025 International
Tweet media one
0
0
0
@Dr_MSU
Mehmet S Uyanik, MD
2 months
The neoantigens that result from the splicing errors are located inside cancer cells. This required a TCR approach that empowers T cells to peer inside other cells and identify if there are abnormal proteins. “It’s akin to giving T cells X-ray vision,” Dr. Klebanoff says.
@MSKCancerCenter
Memorial Sloan Kettering Cancer Center
2 months
In a new study published in @CellPressNews, researchers from MSK and @fredhutch show that it may be possible to develop an #immunotherapy-based approach for #AcuteMyeloidLeukemia and #myelodysplastic syndrome. “This is a potential breakthrough,” says Dr. Omar Abdel-Wahab. “We’re
Tweet media one
0
0
1
@Dr_MSU
Mehmet S Uyanik, MD
2 months
🗣️:🇺🇸/🫂:👨‍⚕️🩸🦀.OS in 😷 w/ transplant-eligible poor-risk AML:.Worst: TP53 mutation+complex karyotype (CK): (2-y OS: 24.5%).Intermediate: TP53 mutation w/o CK(2-y OS: 47.1%).Best: AML-MDS Related (MR) Gene Mutation (OS: 65.7%) & AML-MR-Cytogenetic Abnormality (OS: 60.1%).
Tweet media one
0
0
0
@Dr_MSU
Mehmet S Uyanik, MD
3 months
Should be my wife's grandma (=Eşimin anneannesi).
@gusholderhaber
Gusholder Haber Bülteni
3 months
Esenyurt'ta bir kadın, at arabasıyla park halindeki araca çarpıp kaçtı.
0
0
0